Browse the evidence

Consuming processed meat increases the risk of colorectal cancer, with each 50-gram daily increase linked to an 18% higher risk.

To reduce colorectal cancer risk, limit processed meat intake (bacon, sausage, hot dogs, lunch meats). Each 50g daily increase raises risk by 18%. Be aware that 'nitrite-free' labels often use celery juice, which acts as a nitrate source and carries similar risks. Focus on reducing overall processed meat consumption rather than seeking 'safer' processed alternatives.

An intensive lifestyle intervention (ILI) combining caloric restriction, structured meal replacements, and increased physical activity produces significant initial weight loss and modest long-term maintenance in adults with type 2 diabetes, but does not reduce cardiovascular morbidity or mortality compared to standard education.

For adults with type 2 diabetes, an intensive lifestyle program focusing on moderate caloric restriction (1200-1800 kcal), structured meal replacements (initially 2 meals/day), and 175 minutes of weekly moderate activity can achieve significant weight loss and improve metabolic markers like A1C and lipids. However, do not prioritize weight loss over glucose management or quality of life. Expect some weight regain after the first year, but maintain the focus on behavioral adherence and metabolic health, as initial losses provide long-term benefits even if full maintenance is difficult.

Treatment with GLP-1 RAs or GIP/GLP-1 RAs significantly reduces the risk of myocardial infarction (MI) and nonfatal MI in overweight or obese adults without diabetes, but does not significantly reduce the risk of stroke.

In non-diabetic overweight or obese adults, GLP-1 and GIP/GLP-1 receptor agonists significantly lower the risk of heart attacks (myocardial infarction), including nonfatal ones. However, these drugs did not show a significant reduction in stroke risk in this specific population, unlike some findings in diabetic patients.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) by approximately 14% in patients with type 2 diabetes, independent of glucose-lowering effects.

If you have Type 2 Diabetes and are at risk for heart disease, GLP-1 medications (like semaglutide or liraglutide) are proven to significantly lower your risk of heart attack, stroke, and cardiovascular death. These benefits exist even beyond just lowering blood sugar. While injections can cause stomach upset, starting with a low dose and increasing slowly usually manages this. Oral options are also available for some drugs.

GLP-1 receptor agonists significantly reduce the risk of major adverse cardiovascular events (MACE), cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure in both patients with type 2 diabetes and overweight/obese patients without diabetes.

If you have type 2 diabetes or are overweight/obese with cardiovascular risk factors, GLP-1 receptor agonists (like semaglutide or liraglutide) can significantly lower your risk of heart attacks, strokes, and heart failure hospitalizations, regardless of whether you have diabetes. These benefits are seen with both daily and weekly formulations, and oral options exist.

Weight loss of >10% body weight is required to resolve NASH and regress fibrosis, but this is rarely achieved in routine clinical settings.

Aim for >10% weight loss to potentially reverse NASH and fibrosis, but recognize this is difficult. If you cannot achieve this, focus on a Mediterranean diet to improve liver health and insulin sensitivity even without significant weight loss.

Visceral Adipose Tissue (VAT) and ectopic fat deposition are causal drivers of cardiometabolic disease, whereas subcutaneous fat (specifically gluteofemoral adipose tissue, GFAT) is protective, independent of total body weight.

Focus on preserving subcutaneous fat storage capacity (especially in hips/thighs) and reducing visceral/abdominal fat. This is achieved through diet quality and physical activity, not just weight loss. If you have a 'skinny fat' phenotype (normal weight but high visceral fat), your risk is high. If you have a 'healthy obese' phenotype (high weight but low visceral fat and good metabolism), your risk may be lower than expected.

GLP-1 receptor agonists (semaglutide, tirzepatide) induce high rates of reversion to normoglycemia in individuals with prediabetes, but these benefits are largely lost upon discontinuation of the therapy.

GLP-1 medications like semaglutide are highly effective at reversing prediabetes, with nearly all users returning to normal blood sugar levels while taking the drug. However, stopping the medication usually leads to weight regain and the return of prediabetes. Discuss with your doctor whether this is a short-term reset or a long-term management strategy for you.

Semaglutide 2.4 mg weekly reduces major adverse cardiovascular events (MACE) by 20% in people with BMI ≥27 kg/m² and pre-existing cardiovascular disease, independent of diabetes status.

If you are overweight (BMI 27+) and have heart disease, ask your doctor about semaglutide. It has been shown to reduce the risk of heart attack, stroke, or death from heart causes by 20%. This benefit exists even if you don't have diabetes.

The IWQOL-Lite-CT is a validated patient-reported outcome measure that accurately detects clinically meaningful improvements in physical and psychosocial functioning in patients with overweight or obesity undergoing weight management interventions.

Use the IWQOL-Lite-CT to track how weight loss interventions impact patients' daily physical and psychosocial functioning. It is a validated, 20-item questionnaire that provides a comprehensive assessment of treatment benefit from the patient's perspective, suitable for clinical trials and potentially clinical practice to gauge meaningful within-patient change.

Intentional weight loss triggers strong counterregulatory physiological responses, specifically increased hunger and reduced energy expenditure (hypometabolism), which actively defend the original body weight and facilitate rapid weight regain.

Expect that losing weight will make you hungrier and your metabolism slower. This is a biological defense, not a personal failure. To maintain loss, you must actively counterbalance these adaptations, likely through strategies like increased physical activity and specific dietary choices (e.g., fiber) that support metabolic rate, as standard willpower-based approaches often fail against this biological pushback.

Lifestyle interventions (diet/exercise) are the cornerstone of obesity treatment but are rarely sufficient for long-term weight maintenance due to metabolic adaptations.

Lose weight through diet and exercise, but expect your body to fight back. Your metabolism will slow down, and hunger hormones will rise. To keep the weight off, you likely need medical support (medication or surgery) in addition to lifestyle changes.

Discontinuation of GLP-1 based therapies leads to significant weight regain, indicating that obesity requires chronic management rather than short-term treatment.

If you stop taking GLP-1 medications like semaglutide or tirzepatide, you will likely regain the weight you lost. These drugs treat obesity as a chronic condition, meaning they are intended for long-term use to maintain weight loss.

Unhealthy lifestyle factors (current smoking, low physical activity, and low dietary adherence) increase the risk of myocardial infarction and coronary heart disease, with elevated remnant cholesterol explaining 12-21% of this excess risk.

Your lifestyle choices directly impact a specific type of fat in your blood called remnant cholesterol, which contributes to heart disease risk. Quitting smoking, increasing physical activity, and adhering to dietary guidelines can lower these levels, thereby reducing your risk of heart attack and coronary heart disease. This reduction in risk is partly mediated by the improvement in your remnant cholesterol levels.

Obesity medications (OMs) such as semaglutide and tirzepatide provide benefits for adiposity-related conditions independent of weight reduction.

If you are considering obesity medications, ask your doctor about their potential benefits beyond weight loss, such as reducing cardiovascular risk or improving sleep apnea. These benefits may be significant even if weight loss is modest.

Semaglutide (GLP-1 receptor agonist) significantly reduces major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes and established cardiovascular disease.

If you have type 2 diabetes and existing heart disease or high risk, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly reduce the risk of heart attacks, strokes, and cardiovascular death.

Semaglutide slows the progression of chronic kidney disease (CKD) and reduces major kidney disease events in patients with type 2 diabetes.

If you have type 2 diabetes and chronic kidney disease, ask your doctor about semaglutide. It is a once-weekly injection that has been proven to significantly slow the progression of kidney disease and reduce the risk of major kidney events.

Tirzepatide significantly improves all major lipid profile markers (HDL-C, LDL-C, Total Cholesterol, and Triglycerides) in a dose-dependent manner across patients with type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, Tirzepatide (5mg, 10mg, or 15mg) significantly improves your cholesterol and triglyceride levels in a dose-dependent way. It raises 'good' HDL cholesterol and lowers 'bad' LDL cholesterol and triglycerides more effectively than placebo, and potentially better than other GLP-1 drugs. The benefits increase with higher doses (up to 15mg) over treatment periods of 27-72 weeks. Be aware of injection site reactions and high costs, but the metabolic improvements are robust.

GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and slow kidney function decline in patients with type 2 diabetes, with benefits extending to those with established chronic kidney disease (CKD).

If you have Type 2 Diabetes and kidney issues or heart disease, GLP-1 medications (like Ozempic, Trulicity, or Victoza) are now considered essential, not just optional. They protect your heart and kidneys beyond just lowering blood sugar. Start with a low dose to avoid stomach upset, and work with your doctor to find the right strength. These are often covered by insurance for kidney/heart protection.

Regular physical activity induces systemic molecular adaptations across multiple organ systems, reducing the risk of cardiovascular, metabolic, and mental health diseases through mechanisms involving energy mobilization, structural adaptation, and exerkine signaling.

Make movement a non-negotiable part of your daily routine, not an optional extra. Your body is biologically designed for activity, and regular exercise is one of the most powerful tools you have to prevent heart disease, metabolic issues, and mental health disorders. Focus on consistency across different types of movement (endurance, resistance) to trigger these protective molecular adaptations.

Increased BMI causally increases the risk of coronary artery disease and heart failure, independent of traditional risk factors like blood pressure and diabetes, though these factors mediate a significant portion of the risk.

High body weight directly harms the heart, even if your blood pressure and cholesterol are managed with medication. This is because excess fat tissue itself causes inflammation and stress on the cardiovascular system. Losing weight reduces this independent risk, protecting your heart beyond just improving numbers like blood pressure.

Central adiposity (measured by waist-to-hip ratio) is a stronger predictor of cardiometabolic risk than overall body mass index (BMI), primarily due to visceral fat and limited subcutaneous storage capacity leading to ectopic lipid deposition.

Don't just look at the scale. Where you store fat is critical. Excess fat around your waist (visceral fat) is biologically active and releases harmful substances that lead to diabetes and heart disease, even if your overall weight is normal. Measuring your waist circumference is a better indicator of risk than BMI alone.

GLP-1 receptor agonists (GLP-1RAs) provide significant cardiorenal protection in patients with type 2 diabetes and obesity, reducing major adverse cardiovascular events (MACE) and slowing kidney disease progression independent of, or in addition to, glycemic control and weight loss.

If you have type 2 diabetes or obesity with heart/kidney risks, GLP-1 medications (like semaglutide or liraglutide) are highly effective. They don't just lower blood sugar; they significantly reduce the risk of heart attacks, strokes, and kidney failure. While they can cause temporary stomach upset, the long-term benefits for your heart and kidneys are substantial and proven by large clinical trials. Discuss these options with your doctor, especially if you have existing heart or kidney conditions.

Intensive blood pressure control (target <130/80 mmHg) reduces stroke and macroalbuminuria progression in type 2 diabetes compared to conventional control, without significantly affecting all-cause mortality.

If you have diabetes, aim for a blood pressure target below 130/80 mmHg, especially if you have kidney disease or heart risks. This significantly lowers your risk of stroke and kidney damage. Use home monitoring to get a true average, as clinic readings can be misleading.